A Phase 3 clinical trial (NCT04756037) investigating relugolix combination therapy for contraception completed its primary phase on 2025-02-18. The study, which enrolled 1020 participants, aimed to assess the contraceptive efficacy and safety of the therapy.
Background
Relugolix combination therapy is being investigated for its potential as a contraceptive. This particular study focused on women with uterine fibroids or endometriosis who are at risk for pregnancy, assessing both safety and contraceptive efficacy.
Trial design
The completed trial, NCT04756037, is a Phase 3 study that enrolled 1020 participants. The study's brief summary indicates its purpose is to assess the contraceptive efficacy of relugolix combination therapy in women with Contraception needs, specifically those with uterine fibroids or endometriosis who are at risk for pregnancy.
What this means
The primary completion of this Phase 3 trial signifies that data collection for the study's primary objectives has concluded. Researchers will now proceed with analyzing the collected data to evaluate the safety and contraceptive efficacy of relugolix combination therapy.
Source
The information regarding the primary completion of this clinical trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04756037 was posted on 2025-02-18 on clinicaltrials.gov.